UNCY · Unicycive Therapeutics, Inc.
$5.45
-0.13 (-2.33%)
At close · Aug 20
Market Cap
$151.81M
Shares
27.86M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.45
Open$5.60
Day$5.41–5.68
52W close$3.74–8.56
Avg vol 30d823K
Short int4.3M · 15.5% float · 5.1d
Short vol60%
DataJun 2025–Aug 2026
Filing10-Q · Aug 12
Raw chart and full-history price indicators begin at the captured split on Jun 20, 2025; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−15%
below
Price vs 50-day avg
−7%
below
RSI (14)
50
neutral
MACD trend
Positive
52-week position
35%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
−21%
trailing
YTD return
−6%
this year
Relative strength
−33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
+55% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.55% of float · ▼ -12.3% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
79 holders — near 3-yr high, broad support
Squeeze score
57
elevated · 0–100
Fundamentals
Revenue growth
−29%
Y/Y
EPS growth
+70%
Y/Y
Free cash flow
$-31.3M
Balance sheet
$29.2M
net cash
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−15%
Bearish
Price vs 50-day avg
−7%
Bearish
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
35%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $6 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
+55% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.55% of float · ▼ -12.3% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
79 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $5 · 35%
Range high $9
vs 200-day avg -15%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
UNCY
this stock
Unicycive Therapeutics, Inc.
|
$151.81M | -5.5% | -29.0% | — | 15.5% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Jun 20, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| UNCY | +0.9% | -0.2% | -21.4% | +8.8% | -5.6% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +2.9% | -3.5% | -32.5% | +6.7% | -17.4% |
Key facts
CIK
1766140
CUSIP
90466Y202
13F (30d)
81 filings
79 filers
Visit website
Investor relations